How Pacira BioSciences is aligning EXPAREL with value-based orthopedic care trends
Find out how Pacira BioSciences is positioning EXPAREL within value-based orthopedic care and opioid-sparing recovery trends.
Pharma & Biotech
Pharma & Biotech
How NewcelX Ltd. is pursuing durable islet graft survival in the race for a functional diabetes cure
How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.
Pharma & Biotech
Why BridgeBio Pharma, Inc.’s BBP-418 priority review could redefine the future of LGMD treatment
BridgeBio Pharma, Inc.’s BBP-418 wins FDA Priority Review for LGMD2I/R9. Discover what this could mean for rare muscular dystrophy treatment.
Pharma & Biotech
How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Pharma & Biotech
Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?
Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.
Pharma & Biotech
Why ARTHEx Biotech’s ATX-01 update could reshape RNA-targeted therapy in myotonic dystrophy
Find out how ARTHEx Biotech’s ATX-01 data could reshape RNA-targeted therapy for myotonic dystrophy today!
Pharma & Biotech
How CordenPharma’s AmbioPharm deal strengthens U.S. and China peptide API supply
Find out how CordenPharma’s AmbioPharm deal expands peptide API capacity and reshapes global CDMO competition.
Pharma & Biotech
Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Pharma & Biotech
Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Pharma & Biotech
Can Curi Bio’s Curiverse solve the scalability problem in human-relevant drug discovery?
Human-relevant drug screening is hitting a scale problem. Curi Bio’s Curiverse aims to turn 3D tissue models into industrial workflows.